

Quit Smoking Drugs Market Drivers 2025-2029: Regional Outlook and Sizing Analysis

The Business Research Company's Quit Smoking Drugs Global Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, November 25, 2025 /EINPresswire.com/ -- Get 20% Off All Global Market Reports With Code



ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors

Quit Smoking Drugs Market Growth Forecast: What To Expect By 2025?

The market for cessation smoking medications has seen a significant expansion in the past few



Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors

> The Business Research Company

years. It is projected to escalate from \$39.26 billion in 2024 to \$44.23 billion in 2025, maintaining a compound annual growth rate (CAGR) of 12.7%. The impressive growth during the precedented years can be credited to factors such as public health education initiatives, advances in medicine, government programs, integration of behavioral therapy, and changes in consumer attitudes.

The market for anti-smoking drugs is projected to experience fast-paced growth in the forthcoming years. It is anticipated to expand to ""\$78.3 billion in 2029, clocking a compound annual growth rate (CAGR) of 15.4%. The

growth for the prediction period can be accredited to the investments in research and development, rising demand for quitting aids, strategic marketing, and awareness initiatives, as well as advancements in drug therapies. Key trends during the forecast period are the adoption of personalized treatment methods, escalating health mindfulness, digital therapeutics and applications, incorporation of behavioral therapy, and focused marketing and education.

Download a free sample of the quit smoking drugs market report: https://www.thebusinessresearchcompany.com/sample.aspx?id=9247&type=smp What Are Key Factors Driving The Demand In The Global Quit Smoking Drugs Market? The escalating incidence of smoking addiction is anticipated to drive the expansion of the market for quit-smoking drugs. Smoking involves the inhalation and exhalation of vapors from burned materials like marijuana, hashish, tobacco, and more. Drugs designed to help quit smoking work by curbing an individual's desire for tobacco, serving as a prescribed medication to manage nicotine withdrawal symptoms and assist successfully in ceasing smoking. For example, as per Statistics Canada, a governmental agency in Canada, there was an increase of 5.8% in cigarette production in July 2022 when compared to June 2021. Moreover, the total quantity of cigarettes sold saw a 1.3% rise from May 2022, hitting 1.4 billion in June 2022. Consequently, the escalating incidence of smoking addiction fuels the expansion of the quit-smoking drug market.

Who Are The Leading Players In The Quit Smoking Drugs Market? Major players in the Quit Smoking Drugs include:

- 22nd Century Group
- Cipla Limited
- Dr. Reddy's Laboratories
- GSK Plc.
- Johnson & Johnson
- NJOY LLC
- Novartis AG
- Perrigo Company Plc
- Pfizer Inc.
- Philip Morris International

What Are Some Emerging Trends In The Quit Smoking Drugs Market?

Advancements in product development are gaining traction as a significant trend in the antismoking medication industry. Major enterprises in this segment are keen on developing innovative products to solidify their market standing. For example, in August 2022, Swedish Match AB, a tobacco company based in Sweden, introduced ZYN Tobacco Gold, a tobaccoflavored nicotine pouch that is available at travel retailers. The Tobacco Gold comes in two strengths, medium (3 mg) and strong (6 mg). The pouches have a sweet, tobacco taste reminiscent of dried fruit, wood, and caramel, meeting consumers' preferences since tobacco has become the favored flavor that encourages consumers to select less hazardous alternatives which are both tobacco-free and smoke-free. It serves as a solution for individuals who want to stop tobacco usage but still enjoy a nicotine buzz in smoke-free settings.

Analysis Of Major Segments Driving The Quit Smoking Drugs Market Growth The quit smoking drugs market covered in this report is segmented –

- 1) By Product: Drug Therapy, E-Cigarettes, Nicotine Inhalers, Nicotine Replacement Therapies, Nicotine Sublingual Tablets
- 2) By Drug: Varenicline (Chantix), Bupropion (Zyban), Other Drugs
- 3) By Distribution: Drug Store, Online Pharmacies, Retail Pharmacies

Subsegments:

- 1) By Drug Therapy: Bupropion (Zyban), Varenicline (Chantix)
- 2) By E-Cigarettes: Disposable E-Cigarettes, Rechargeable E-Cigarettes, Pod Systems
- 3) By Nicotine Inhalers: Prescription Inhalers, Over-The-Counter Inhalers
- 4) By Nicotine Replacement Therapies (NRT): Nicotine Patches, Nicotine Gum, Nicotine Lozenges
- 5) By Nicotine Sublingual Tablets: Fast-Acting Sublingual Tablets, Extended-Release Sublingual Tablets

View the full quit smoking drugs market report:

https://www.thebusinessresearchcompany.com/report/quit-smoking-drugs-global-market-report

Which Region Is Expected To Lead The Quit Smoking Drugs Market By 2025? In 2024, North America dominated the quit smoking drugs market in size. The projected growth status of this regional market is included in the report. It comprehensively covers other regions as well, namely Asia-Pacific, Western Europe, Eastern Europe, South America, Middle East, and Africa.

Browse Through More Reports Similar to the Global Quit Smoking Drugs Market 2025, By The Business Research Company

Cardiovascular Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Dermatology Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Gastrointestinal Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: saumyas@tbrc.info

The Business Research Company - <u>www.thebusinessresearchcompany.com</u>

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn

LinkedIn Facebook

Χ

This press release can be viewed online at: https://www.einpresswire.com/article/869841487

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.